Figure 1.


A
Glycerol release (rate as control)
0
1
2
3
4
a
d
b
e
c
f
*
*
*
12 h
24 h
0
0.75
1.5
IP (mg/mL)
B
Viability (%)
0
20
40
60
80
100
120
*
*
0
0.5
1
1.5
2
2.5
3
4
5
IP (mg/mL)

Figure 2.


PPARγ
HSL
ATGL
mRNA expression (% as control)
120
100
80
60
40
20
0
*
0
1.5
IP (mg/mL)

Figure 3.


A
a
Perilipin
ATGL
GAPDH
0
0.75
1.5
0
0.75
1.5
Iso
12h
24h
4h
IP (mg/mL)
b
ATGL/GAPDH
1.4
1.2
1
0.8
0.6
0.4
0.2
0
§§
*
§§
*
12 h
24 h
0
0.75
1.5
IP (mg/mL)
B
a
HSL Ser563
HSL Ser660
HSL
0
0.75
1.5
0
0.75
1.5
Iso
12h
24h
4h
IP (mg/mL)
b
HSL 563/HSL
1
0.8
0.6
0.4
0.2
0
12 h
24 h
0
0.75
1.5
IP (mg/mL)

c



Figure 4.


A
Glycerol release (rate as control)
0
1
2
3
4
12 h
24 h
*
*
#
#
IP (mg/mL) 0 0.75 1.5 0 0.75 1.5 0 0.75 1.5
U0126 μmol/L – – – 50 50 50 – – –
H89 μmol/L – – – – – – 10 10 10
B
a
pERK
ERK
GAPDH
IP (mg/mL) 0 0.75 1.5 1.5 0 0.75 1.5 1.5
U0126 μmol/L – – – 50 – – – 50
12h
24h
b
pERK/ERK
0
0.2
0.4
0.6
0.8
1
*
**
§
¤¤
ǂǂ
12 h
24 h
IP (mg/mL) 0 0.75 1.5 1.5
U0126 (μmol/L) – – – 50